- Medtronic plc (NYSE:MDT) announced early data for its self-expanding Intrepid transcatheter mitral valve replacement (TMVR) system for mitral valve regurgitation (MR) utilizing the transfemoral access route.
- Data from the first 15 patients enrolled in an Early Feasibility Study of the Intrepid Transfemoral System showed 100% survival and no stroke, a median procedure time of 46 minutes, and none/trace MR in all implanted patients at 30 days.
- The data were published simultaneously in the American College of Cardiology (JACC): Cardiovascular Intervention.
- Mitral regurgitation (MR) occurs when blood flows backward through the mitral valve and into the atrium when the left ventricle contracts.
- The Intrepid valve has been used to treat more than 350 patients as part of global clinical trials.
- The Intrepid TMVR system is only available for investigational use, and it is not approved outside of clinical studies.
- Related: Medtronic Touts 5-Year Data Of Self-Expanding TAVR Platform.
- Price Action: MDT shares closed at $122.98 on Friday.
Medtronic’s Intrepid Valve Eliminates Mitral Regurgitation At 30 Days, Study Shows
Medtronic plc (NYSE:MDT) announced early data for its self-expanding Intrepid transcatheter mitral valve replacement (TMVR) system for mitral valve regurgitation (MR)…
Related Posts
Morgan Stanley Maintains Overweight on Sophia Genetics, Lowers Price Target to $18
Morgan Stanley maintains Sophia Genetics (NASDAQ:SOPH) with a Overweight and lowers the price target from $23 to $18.
Stifel Initiates Coverage On Intapp with Buy Rating, Announces Price Target of $40
Stifel analyst Tom Roderick initiates coverage on Intapp (NASDAQ:INTA) with a Buy rating and announces Price Target of $40.